(Q51376974)

English

Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study.

scientific article published in July 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/21410628

Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study. (English)

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/21410628

type 2 diabetes

0 references

0 references

1 reference

ChEBI release 2020-05-28

1 reference

based on heuristic

inferred from title

author name string

R Gomis

1

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/21410628

R-M Espadero

2

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/21410628

R Jones

3

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/21410628

H J Woerle

4

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/21410628

K A Dugi

5

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/21410628

publication date

1 July 2011

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/21410628

Diabetes, Obesity and Metabolism

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/21410628

13

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/21410628

7

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/21410628

653-661

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/21410628

Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01391.X

21 January 2018

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01391.X

21 January 2018

DPP-4 Inhibitors and Combined Treatment in Type 2 Diabetes: Re-evaluation of Clinical Success and Safety

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01391.X

21 January 2018

(R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared wi

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01391.X

21 January 2018

Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01391.X

21 January 2018

Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01391.X

21 January 2018

Binding to dipeptidyl peptidase-4 determines the disposition of linagliptin (BI 1356)--investigations in DPP-4 deficient and wildtype rats

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01391.X

21 January 2018

The metabolism and disposition of the oral dipeptidyl peptidase-4 inhibitor, linagliptin, in humans

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01391.X

21 January 2018

Evaluation of the potential for steady-state pharmacokinetic and pharmacodynamic interactions between the DPP-4 inhibitor linagliptin and metformin in healthy subjects.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01391.X

21 January 2018

Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01391.X

21 January 2018

Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01391.X

21 January 2018

Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01391.X

21 January 2018

Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of β-cell function in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01391.X

21 January 2018

Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01391.X

21 January 2018

Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01391.X

21 January 2018

Oral antihyperglycemic therapy for type 2 diabetes mellitus.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01391.X

21 January 2018

Overview of the gliptin class (dipeptidyl peptidase-4 inhibitors) in clinical practice

1 reference

https://api.crossref.org/works/10.1111%2FJ.1463-1326.2011.01391.X

21 January 2018

Identifiers

10.1111/J.1463-1326.2011.01391.X

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/21410628

1 reference

Europe PubMed Central

4 April 2018

http://europepmc.org/abstract/MED/21410628

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51376974&oldid=1202105421"